Pharmacometrics and Pharmacokinetics (PMK) Community

Community Goals

Scientific Expertise 
The PMK Community is developing as a unique resource to learn about newer applications of pharmacometrics and pharmacokinetics and best practices via programming, webinars and white papers enabled by participation of members with diverse interests (pharmacokineticists, statistical pharmacometricians, PBPK experts, transporter experts from industry, academia, and regulatory, and student/trainees).

Catalyst for Innovation
Hosts educational forums to promote emerging areas of influence by thought-leaders. Also contributes to establishing point-counterpoint formats to discuss hot topics to enhance the attendee experience at Annual Meetings.

Influence and Impact
Currently working to identify at least one focus area for which a concept outline will be developed for a Best Practice White Paper followed by 2-year goal to publish an article.

Education and Communication
The PMK Community is exploring opportunities to set up a model library to capture pertinent technical information to supplement information in published articles from select journals. PMK is also active on social media will ensuring frequent communication with members.

Organizational Effectiveness
PMK has established Steering Committee membership along with general roles & expectations necessary to align with contributions with other Community goals. The Community is also developing a communication outreach plan to Community members to announce key dates and news updates.

Community News
Please log in as a member to access more Community News and members-only content.


Yu-Nien (Tom) Sun, PhD
Janssen BioTherapeutics

Yu-Nien (Tom) Sun, PhD is Senior Director of the Oncology PK/PD Group, Biologics Clinical Pharmacology Department at Janssen BioTherapeutics (JBIO), Janssen Research & Development, LLC.  His recent research focus has been the application of innovative pharmacometric approaches for model-based drug development in oncology. Read his full bio here.
Vice Chair
Michael A. Tortotrici, PharmD, PhD
CSL Behring

Dr. Michael A. Tortorici is a Director of Clinical Pharmacology & Early Development at CSL Behring based in Philadelphia, PA, since 2014.  Dr. Tortorici received his PharmD from the University of Pittsburgh in 2002 and his PhD in Pharmaceutical Sciences from the University of Pittsburgh in 2007. Read his full bio.

Past Chair

Sriram Krishnaswami, PhD
Pfizer Global Research and Development


Dr. Sriram Krishnaswami is Senior Director in the Department of Clinical Pharmacology at Pfizer, Groton, CT. His research interests include designing dose-finding strategies using modeling and simulation for new chemical entities for diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus and for the prevention of transplant rejection. Read his full bio here.

Join the PMK Community >>

Get more involved in the PMK Community >>

Find PMK Community Members >>
528 N Washington St, Alexandria, VA 22314 |  Ph: 703.836.6981 |